International Flavors & Fragrances Inc. filed SEC Form 8-K: Leadership Update

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):June 9, 2025 (June 3, 2025)

---

(Exact Name of Registrant as Specified in its Charter)

---

 

Registrant’s telephone number, including area code: (212) 765-5500

  

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Virginia Drosos, 62, previously served as Chief Executive Officer and director of Signet Jewelers Ltd. (“Signet”), the world’s largest retailer of diamond jewelry, from August 2017 to November 2024. During her tenure, she led Signet through a significant transformation, expanding its digital capabilities and enhancing the customer experience. Prior to Signet, Ms. Drosos was Chief Executive Officer of Assurex Health, Inc. (“Assurex”), where she delivered significant revenue growth and executed the strategic sale of Assurex to Myriad Genetics. Prior to her role at Assurex, she spent 25 years at Procter & Gamble (NYSE: PG), where she established herself as a transformative leader who led game changing innovation, built multi-billion-dollar brands, and reinvented global categories. She currently serves as a director of Foot Locker Inc. and the United States Golf Association and previously held board positions at Akron Children’s Hospital and American Financial Group, Inc., where she served on the audit and governance committees.

The Board has determined that Ms. Drosos qualifies as an independent director under the applicable rules and regulations of the New York Stock Exchange and the Company’s Board independence requirements.

There is no arrangement or understanding between Ms. Drosos and any other persons, pursuant to which Ms. Drosos was appointed to serve on the Board. Additionally, there has not been any transaction or currently proposed transaction, in which the Company was or is to be a participant and the amount involved exceeds $120,000, and in which Ms. Drosos had or will have a direct or indirect material interest since the beginning of IFF’s last fiscal year.

Ms. Drosos will participate in the non-employee director compensation arrangements described in IFF’s 2024 Proxy Statement, which was filed with the Securities and Exchange Commission on March 18, 2025.

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

---